HRT Financial’s Relay Therapeutics RLAY Stock Holding History

HRT Financial’s Portfolio RLAY Stock Details RLAY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$374K	Buy	+20,000	New	+$290K	﹤0.01%	2915

Other funds holding RLAY

SIAU

SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return

HRT Financial's RLAY Position: Q1 2026 in Review

HRT Financial sold out of Relay Therapeutics (RLAY) in Q1 2026, closing a stake of 30,645 shares — an estimated $259K sold.

HRT Financial first reported a position in RLAY in Q2 2023 and held it in 7 quarters. The position peaked at $1.03M in Q3 2025. 244 funds tracked by Wall St. Rank hold RLAY as of Q1 2026.

HRT Financial reported no remaining Relay Therapeutics position as of Q1 2026 after selling out during the quarter.
HRT Financial sold 30,645 Relay Therapeutics shares in Q1 2026, an estimated $259K.
HRT Financial first reported a position in Relay Therapeutics in Q2 2023 and held it in 7 quarters.
HRT Financial's Relay Therapeutics position peaked at $1.03M in Q3 2025.
244 funds tracked by Wall St. Rank held Relay Therapeutics as of Q1 2026.

Based on HRT Financial's 13F filing for Q1 2026, filed 14 May 2026.